Endocrine Abstracts

Background: Treatment of neuro-endocrine tumors (NETs) is often challenging, given the heterogeneity of primary tumor sites, the individual disease complexity and the variety of treatment options. If patients are progressive during first-line treatment with somatostatin analogues (SSA), peptide receptor radionuclide therapy (PRRT) is a validated treatment for somatostatin receptor overexpressing neuroendocrine tumors. The NETTER-1 trial has demonstrated a pronounced positive e...